Matthew W. Foehr
2014 - Ligand Pharmaceuticals
In 2014, Matthew W. Foehr earned a total compensation of $4.1M as President and Chief Operating Officer at Ligand Pharmaceuticals, a 106% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $187,900 |
|---|---|
| Option Awards | $3,115,177 |
| Salary | $375,360 |
| Stock Awards | $372,100 |
| Other | $5,400 |
| Total | $4,055,937 |
Foehr received $3.1M in option awards, accounting for 77% of the total pay in 2014.
Foehr also received $187.9K in non-equity incentive plan, $375.4K in salary, $372.1K in stock awards and $5.4K in other compensation.
Rankings
In 2014, Matthew W. Foehr's compensation ranked 2,089th out of 13,032 executives tracked by ExecPay. In other words, Foehr earned more than 84.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,089 out of 13,032 | 84th |
Division Manufacturing | 739 out of 4,966 | 85th |
Major group Chemicals And Allied Products | 232 out of 1,686 | 86th |
Industry group Drugs | 179 out of 1,365 | 87th |
Industry Pharmaceutical Preparations | 149 out of 1,043 | 86th |
Source: SEC filing on April 14, 2017.
Foehr's colleagues
We found four more compensation records of executives who worked with Matthew W. Foehr at Ligand Pharmaceuticals in 2014.